Lanean...
Early Failure of Frontline Rituximab-containing Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma does not Predict Futility of Autologous Hematopoietic Cell Transplantation
The poor prognosis of diffuse large B-cell lymphoma (DLBCL) patients relapsing within 1-year of initial diagnosis after first-line rituximab-based chemoimmunotherapy has created controversy about the role of autologous transplantation (auto-HCT) in this setting. We compared auto-HCT outcomes of chem...
Gorde:
Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
2014
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4194275/ https://ncbi.nlm.nih.gov/pubmed/25008330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2014.06.036 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|